SciGen Limited : Closing of Transaction

The Board of Directors of SciGen Limited (ASX:SIE) ("SciGen") announce that it has closed the transaction on the sale of 49.99% of SciGen's interest in SciGen BioPharma Pvt Ltd ("SciGen BioPharma") to Tek-Gen Holdings Limited ("TGH"), in accordance with the Investment Agreement dated March 15, 2010 signed with Anglo Gulf Ltd.
TGH, a company incorporated in Cyprus is part of a Group which has over 30 years presence in the pharmaceutical industry and has extensive experience in the development, sales and marketing of biotechnology derived and other pharmaceutical products on international markets.
SciGen now holds 50.01% of the equity interest in SciGen BioPharma. SciGen has entered into a shareholders' agreement with TGH in respect of the ongoing corporate governance arrangements of SciGen BioPharma.
SciGen BioPharma is in the process of the final development of a biotechnological pharmaceutical production facility located in Pune, India, which is intended to manufacture recombinant human insulin and other biotechnology products in accordance with European and American standards. The facility is expected to be fully operational by the end of 2012.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.
SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster
entry into the market, as the biogeneric products have undergone much of the clinical

SciGen Limited ARBN 101 318 852 Suite 1, 13B Narabang Way, Belrose, NSW 2085 Australia

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com
development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.
SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.
SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facility in India and a contract manufacturer
in Poland, Bioton S.A.

SciGen Limited ARBN 101 318 852 Suite 1, 13B Narabang Way, Belrose, NSW 2085 Australia

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com

distributed by